Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Amgen
Ain Shams University
Pfizer
University of Maryland, Baltimore
Swiss Pediatric Oncology Group
Children's Hospital of Michigan
Sun Yat-sen University
Federal University of Minas Gerais
PETHEMA Foundation
Sanofi
East Valley Hematology and Oncology Medical Group